TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33605543

Group type: EXPERIMENTAL
Intervention: dHAM (dried human amnion derived membrane)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: dHAM
Number of subjects: 31
Study: 33833219

Group type: EXPERIMENTAL
Intervention: Genetic liability to BIP-SCZ (bipolar disorder and schizophrenia combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic instruments of BMI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic liabilities to COVID-19 phenotypes
Number of subjects: 0
Study: 33032804

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (100 μg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (BNF) with 25 mL of 0.375% ropivacaine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (BNF) with 25 mL of 0.25% ropivacaine
Number of subjects: 83
Study: 36202690

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study: 33546942

Group type: EXPERIMENTAL
Intervention: High dose anthocyanins (201 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low dose anthocyanins (47 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 33198608

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Number of subjects: 11016

Group type: COMPARATOR
Intervention: Placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Number of subjects: 11016

Group type: EXPERIMENTAL
Intervention: Ticagrelor added to aspirin
Number of subjects: 11016

Group type: COMPARATOR
Intervention: Placebo added to aspirin
Number of subjects: 11016

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11016

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11016
Study: 35061867

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5674
Study: 33115598

Group type: EXPERIMENTAL
Intervention: CBJ with 1000 mg of vitamin C (NC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CBJ with matched placebo (N)
Number of subjects: 18
Study: 32524145

Group type: EXPERIMENTAL
Intervention: Ultrasound‐mediated transdermal drug delivery (group U)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lidocaine intradermal injection (group I)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 58
Study: 32698620

Group type: EXPERIMENTAL
Intervention: Thinking about a negative health outcome in the future
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facing an actual health outcome (consuming an unhealthy food)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact biases associated with behavioral motivation
Number of subjects: 0
Study: 34478693

Group type: EXPERIMENTAL
Intervention: HF disease management program (HF-DMP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study: 32566244

Group type: EXPERIMENTAL
Intervention: PSPAF intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 34498896

Group type: EXPERIMENTAL
Intervention: Recovering Together (RT) intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Health education attention placebo control
Number of subjects: 58
Study: 33267853

Group type: EXPERIMENTAL
Intervention: Intention to stop khat chewing
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Self-reevaluation
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Environmental reevaluation
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Social liberation
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Additional substances daily, khat dependency, early age initiation of khat chewing
Number of subjects: 605
Study: 33748282

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg orally 30 min before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33990064

Group type: EXPERIMENTAL
Intervention: Physical activity in adolescence
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Continuous physical activity from youth to adulthood
Number of subjects: 843
Study: 34175714

Group type: EXPERIMENTAL
Intervention: Stepped‐care (SC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 53
Study: 35946240

Group type: EXPERIMENTAL
Intervention: 0.5% minocycline mouth rinse prescribed along with vitamin supplement and topical anesthetic gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical anesthetic gel and vitamin supplement alone
Number of subjects: 60
Study: 33704389

Group type: EXPERIMENTAL
Intervention: Clear masks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Covered masks
Number of subjects: 200
Study: 32711948

Group type: EXPERIMENTAL
Intervention: Active distraction (rotatable wooden toy)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Passive distraction (toy wristband)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study: 35568376

Group type: EXPERIMENTAL
Intervention: Coaching intervention (6 telephone-delivered individual coaching sessions over 12 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 250
Study: 33404150

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent buprenorphine-naloxone (ACB)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No behavioral counseling
Number of subjects: 234

Group type: COMPARATOR
Intervention: No ACB
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 234
Study: 33115831

Group type: EXPERIMENTAL
Intervention: CSNAT-I (Carer Support Needs Assessment Tool intervention)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 437
Study: 35381095

Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) at 1000- and 1500-mg doses twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33801189

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 39

Group type: COMPARATOR
Intervention: General gymnastics (CG)
Number of subjects: 39
Study: 33827289

Group type: EXPERIMENTAL
Intervention: Possible treatment for children with profound autism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for research
Number of subjects: 0
Study: 32721580

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 33713618

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 200
Study: 32244628

Group type: EXPERIMENTAL
Intervention: Five sets of five bench press repetitions at 90% 1 repetition maximum (1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Five sets of three bench press repetitions at 95% 1 repetition maximum (1RM)
Number of subjects: 10
Study: 35181572

Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg twice daily (BID)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg at bedtime (HS)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: APT‐1011 1.5 mg BID
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: APT‐1011 1.5 mg HS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg BID
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg HS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: All active groups
Number of subjects: 106
Study: 33966331

Group type: EXPERIMENTAL
Intervention: HBAI20 vaccine
Number of subjects: 133

Group type: COMPARATOR
Intervention: HBVaxPro®-10 µg
Number of subjects: 133
Study: 35271409

Group type: EXPERIMENTAL
Intervention: Eccentric exercise with biceps vibration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eccentric exercise without biceps vibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive movement with biceps vibration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive movement without biceps vibration
Number of subjects: 0
Study: 33183032

Group type: EXPERIMENTAL
Intervention: Ningxin Anshen Decoction (NXAS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32368860

Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 17
Study: 35526235

Group type: EXPERIMENTAL
Intervention: Actual potency of factor VIII concentrate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Label potency of factor VIII concentrate
Number of subjects: 50
Study: 34881912

Group type: EXPERIMENTAL
Intervention: Integrated psychotherapy
Number of subjects: 113
Study: 35604581

Group type: EXPERIMENTAL
Intervention: 6-month intradialytic moderate-intensity aerobic exercise training program (3 times a week for 60 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EX group
Number of subjects: 24
Study: 34864978

Group type: EXPERIMENTAL
Intervention: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fast thrombolytic regimen (50 mg of rtPA infused in 6h)
Number of subjects: 120
Study: 36409949

Group type: EXPERIMENTAL
Intervention: Electronic health assessment with individualized feedback
Number of subjects: 296

Group type: COMPARATOR
Intervention: Screening program without feedback (Control)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 296
Study: 33107745

Group type: EXPERIMENTAL
Intervention: IV administration of cefquinome sulfate (2 mg/kg)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: IM administration of injectable cefquinome sulfate (2 mg/kg)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: IM administration of injectable cefquinome sulfate suspension (2 mg/kg)
Number of subjects: 432
Study: 34621044

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally every day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33440015

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: I-gel® supraglottic airway device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endotracheal tube intubation by direct laryngoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laryngeal mask (LM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laryngeal tube (LT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 20
Study: 32266599

Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg/kg every 12 h
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vancomycin 12 mg/kg every 8 h
Number of subjects: 19
Study: 32594832

Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy telerehabilitation via smartphone (Caspar Health e-system and mobile app)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Paper-and-pencil instructions for the home programme
Number of subjects: 31
Study: 33595142

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) 100 IU/2 mL in each adductor magnus and each triceps surae
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline 0.9% (2 mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 55
Study: 32790724

Group type: EXPERIMENTAL
Intervention: CPEC projects with land acquisition by force or inadequate compensation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Regions with economic zones
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Communities with development projects
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Expectations of financial outcomes for CPEC projects
Number of subjects: 250
Study: 35470143

Group type: EXPERIMENTAL
Intervention: Highly malignant EEG patterns
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Malignant EEG patterns
Number of subjects: 262

Group type: COMPARATOR
Intervention: Benign EEG patterns
Number of subjects: 262

Group type: COMPARATOR
Intervention: Continuous EEG background
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: EEG background and amount of discharges
Number of subjects: 262
Study: 33471640

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors alone
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors plus basal insulin
Number of subjects: 585

Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 585
Study: 34081111

Group type: EXPERIMENTAL
Intervention: BHB + BLG
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BLG
Number of subjects: 8
Study: 32213768

Group type: EXPERIMENTAL
Intervention: Na2FPO3/CaCO3 toothpaste with 1,378 microg F/g of total soluble fluoride (TSF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 1,160 microg F/g TSF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 900 microg F/g TSF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 597 microg F/g TSF
Number of subjects: 10
Study: 35789454

Group type: EXPERIMENTAL
Intervention: Tooth tissue‐borne expander
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tooth-borne expander
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bone-borne expander
Number of subjects: 46
Study: 33395602

Group type: EXPERIMENTAL
Intervention: Primary disgust appraisal reappraisal script
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Secondary disgust appraisal reappraisal script
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control condition (no reappraisal script)
Number of subjects: 52
Study: 36149910

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 19
Study: 34028359

Group type: EXPERIMENTAL
Intervention: Health care mode exercise prescriptions
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Scientific fitness mode exercise prescriptions
Number of subjects: 177
Study: 35794786

Group type: EXPERIMENTAL
Intervention: Reminder letter in addition to standard information (intervention group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 136
Study: 33677411

Group type: EXPERIMENTAL
Intervention: Prednisone taper
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32990919

Group type: EXPERIMENTAL
Intervention: Peg‐IFN–NA SOT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Peg‐IFN monotherapy
Number of subjects: 132
Study: 35318238

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) during exercise
Number of subjects: 18
Study: 34052096

Group type: EXPERIMENTAL
Intervention: SHBG-raising therapies
Number of subjects: 0
Study: 35766658

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with daily multidisciplinary rounds by remote intensivists
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 30
Study: 33413462

Group type: EXPERIMENTAL
Intervention: EAA + W (34.7 g protein, 24 g EAA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MEAL (34.7 g protein, 11.4 g EAA)
Number of subjects: 10
Study: 35665994

Group type: EXPERIMENTAL
Intervention: 5-session psychological intervention for chronic pain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 32039934

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Pain improvement at week 4
Number of subjects: 1241
Study: 34860207

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30-day mindfulness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 0
Study: 32609036

Group type: EXPERIMENTAL
Intervention: 90-minute training workshop on ICD management conversations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preworkshop self-assessment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postworkshop self-assessment
Number of subjects: 40
Study: 35987472

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Tocilizumab + Standard of Care (SOC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 12
Study: 33177818

Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 82
Study: 36366206

Group type: EXPERIMENTAL
Intervention: Active Stretching (AS) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study: 32426884

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fumaric Acid Esters (FAE)
Number of subjects: 65
Study: 34684499

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training 2 times a week (T2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training 4 times a week (T4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the comparison between T2 and T4)
Number of subjects: 20
Study: 33118602

Group type: EXPERIMENTAL
Intervention: THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of CBD), initial dose of one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day, increased according to symptoms
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 33962656

Group type: EXPERIMENTAL
Intervention: Intraperitoneal microdialysis catheter implanted at the end of surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care (no microdialysis catheter)
Number of subjects: 200
Study: 36258217

Group type: EXPERIMENTAL
Intervention: TCM granules combined with PPI step-down therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: TCM granules placebo combined with PPI step-down therapy
Number of subjects: 174
Study: 34793265

Group type: EXPERIMENTAL
Intervention: CJC-1134-PC (2 mg single dose or titrated doses of 2 + 3 and 2 + 3 + 4 mg at weekly intervals)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: CJC-1134-PC (1, 2, 3, and 4 mg weekly doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 35033029

Group type: EXPERIMENTAL
Intervention: Web-based EHR-integrated prediabetes CDS intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 32946978

Group type: EXPERIMENTAL
Intervention: First set of coated tablets
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Second set of coated tablets
Number of subjects: 135
Study: 35635326

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 763
Study: 32556157

Group type: EXPERIMENTAL
Intervention: E + sVIP (entecavir + peg‐IFN alfa‐2a [180 µg every week over 48 weeks] plus sequential HBV vaccination [20 µg of HBsAg on weeks 52, 56, 60, and 76])
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: E + cVIP (entecavir + peg‐IFN alfa‐2a + concomitant HBV vaccination [weeks 4, 8, 12, and 28])
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (entecavir only)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: E + sVIP
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: E + cVIP
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 111
Study: 34470536

Group type: EXPERIMENTAL
Intervention: Didactic intervention
Number of subjects: 3386

Group type: EXPERIMENTAL
Intervention: Descriptive harms intervention
Number of subjects: 3386

Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 3386

Group type: EXPERIMENTAL
Intervention: ARISE intervention
Number of subjects: 3386

Group type: COMPARATOR
Intervention: Unbeneficial test condition (0 lives saved)
Number of subjects: 3386

Group type: COMPARATOR
Intervention: Beneficial test condition (1 life saved)
Number of subjects: 3386
Study: 32583011

Group type: EXPERIMENTAL
Intervention: TVT-S (H position)
Number of subjects: 197

Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: TVT-S (U position)
Number of subjects: 197
Study: 32443306

Group type: EXPERIMENTAL
Intervention: Luofengning granule (LFN‐G)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34355279

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Mindfulness
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study: 32691298

Group type: EXPERIMENTAL
Intervention: Rubber drain
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no drain)
Number of subjects: 40
Study: 32348624

Group type: EXPERIMENTAL
Intervention: Guided Biofilm therapy (GBT) with plaque disclosing agent
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control without plaque disclosing agent
Number of subjects: 32
Study: 35551292

Group type: EXPERIMENTAL
Intervention: Dorzagliatin add-on therapy to metformin (1,500 mg per day)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Placebo add-on therapy to metformin (1,500 mg per day)
Number of subjects: 767
Study: 33462708

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Thigh Muscle Density (TMD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 94